CXCR3 and COVID-19: These effects were confirmed by the increased peripheral lymphocytes amount, the decline in the C-reactive protein, and waning of over-activated cytokine-secreting immune cells (CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells) into the blood of COVID-19 patients, by mean 4.5 days later the MSCs intravenous infusion [3].